These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 36776882

  • 1. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X.
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [Abstract] [Full Text] [Related]

  • 2. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
    Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, Wang S, Shen Y, Zhong R, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X.
    J Immunother Cancer; 2024 Apr 18; 12(4):. PubMed ID: 38641349
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors-a retrospective cohort study.
    Guo L, Li J, Wang J, Chen X, Cai C, Zhou F, Xiong A.
    Transl Lung Cancer Res; 2024 Aug 31; 13(8):1975-1987. PubMed ID: 39263031
    [Abstract] [Full Text] [Related]

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ, Zhu HH, Liu YT, Lin L, Xing PY, Hao XZ, Cong MH, Wang HY, Wang Y, Li JL, Feng Y, Hu XS.
    Zhonghua Zhong Liu Za Zhi; 2022 May 23; 44(5):416-424. PubMed ID: 35615798
    [Abstract] [Full Text] [Related]

  • 6. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
    Sánchez-Gastaldo A, Muñoz-Fuentes MA, Molina-Pinelo S, Alonso-García M, Boyero L, Bernabé-Caro R.
    Transl Lung Cancer Res; 2021 Jun 23; 10(6):2509-2522. PubMed ID: 34295658
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N, Jiang J, Tang S, Sun G.
    Int Immunopharmacol; 2020 Aug 23; 85():106677. PubMed ID: 32531712
    [Abstract] [Full Text] [Related]

  • 8. NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer.
    Han R, Zhang F, Hong Q, Visar D, Zhan C, Zhao C, Wang F, Zhang S, Li F, Li J, Mu J.
    Thorac Cancer; 2024 Aug 23; 15(24):1792-1804. PubMed ID: 39034535
    [Abstract] [Full Text] [Related]

  • 9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y.
    J Clin Lab Anal; 2019 Oct 23; 33(8):e22964. PubMed ID: 31282096
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.
    Nguyen CTT, Van TNK, Huong PT.
    Cancer Control; 2024 Oct 23; 31():10732748241285474. PubMed ID: 39285591
    [Abstract] [Full Text] [Related]

  • 12. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K, Wang C, Shi F, Huang Y, Ma L, Li M, Song Y.
    BMC Cancer; 2021 Jan 14; 21(1):66. PubMed ID: 33446134
    [Abstract] [Full Text] [Related]

  • 13. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F, Gu Y, Chen S, Liu Y, Yin W, Zhang Y, Cao B.
    Zhongguo Fei Ai Za Zhi; 2018 Jun 20; 21(6):481-492. PubMed ID: 29945708
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S, Zheng Q, Zhang W, Zhou M, Xia C, Feng W.
    Front Immunol; 2024 Jun 20; 15():1408700. PubMed ID: 39050856
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, Kaira K, Kaburagi T, Minato K, Kobayashi K, Kagamu H.
    Cancer Med; 2021 Oct 20; 10(20):6971-6984. PubMed ID: 34414673
    [Abstract] [Full Text] [Related]

  • 16. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.
    Lung Cancer; 2017 Sep 20; 111():176-181. PubMed ID: 28838390
    [Abstract] [Full Text] [Related]

  • 17. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.
    JAMA Netw Open; 2023 Jul 03; 6(7):e2322915. PubMed ID: 37432682
    [Abstract] [Full Text] [Related]

  • 18. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.
    Lu X, Wan J, Shi H.
    Oncol Lett; 2022 Aug 03; 24(2):266. PubMed ID: 35782904
    [Abstract] [Full Text] [Related]

  • 19. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P.
    ESMO Open; 2021 Oct 03; 6(5):100254. PubMed ID: 34481329
    [Abstract] [Full Text] [Related]

  • 20. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
    Xiong A, Xu J, Wang S, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Nie W, Zhong H, Zhang X.
    Front Immunol; 2023 Oct 03; 14():1173025. PubMed ID: 37304273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.